Bimekizumab in Plaque Psoriasis

计划入组 60 人 · 首次发布于 2024 年 3 月 28 日

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

计划入组 71 人 · 首次发布于 2020 年 2 月 5 日

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

计划入组 189 人 · 首次发布于 2018 年 10 月 16 日

Bimekizumab(Bimzelx)

Ixekizumab(Taltz)

Rx

BKC-005

HAMILTON CDN BK MEAN RVSON IDX ETF UNIT

United States

HAMILTON CDN BK EQUAL-WEIGHT INDEX UNIT CL E

FDA Approves Bimekizumab-bkzx (Bimzelx) for Moderate-to-Severe Hidradenitis Suppurativa

Bimekizumab Gains FDA Approval for Single-Injection Delivery, Expanding Treatment Options

FDA Approves UCB's Bimzelx (bimekizumab-bkzx) for Hidradenitis Suppurativa